Sep 26, 2013 - 4:42 pm
<*** src="https://blu179.mail.live.com/Handlers/ImageProxy.mvc?bicild=&canary=sSvvd76xEh8uThohRB4VU%2f8mL5T96OvrI1dY4cyEkdE%3d0&url=http%3a%2f%2fih.constantcontact.com%2ffs116%2f1102712935813%2f***%2f107.jpg" align="right" width="208" height="210" hspace="5" vspace="5" border="0" style="font-size: 11pt;" />
Matching the right drug to a particular patient's tumor type, though increasingly common in treating certain types of cancer, is not yet the norm for ovarian cancer patients. The Clearity Foundation is trying to change that by providing ovarian cancer patients molecular profiling of their tumors so their physicians can make more informed treatment decisions.
We spoke to Laura Shawver, founder of the organization, about her work, her own experience with the disease, and how the foundation is using personalized medicine to change the way physicians treat patients with ovarian cancer. Click The Burrill Report (September 9, 2013): Bringing Personalized Medicine to Ovarian Cancer (.MP3,19.72 Mb) to listen to the podcast